Last reviewed · How we verify
Combination 1 (combination-1)
Combination 1, developed by Pfizer Inc., is a marketed drug with key indications in Indication 1, Indication 2, and Indication 3. It has undergone 44 clinical trials and has been the subject of 467 publications. The commercial significance of Combination 1 is substantial, but its revenue figures are not available. In terms of clinical differentiation, Combination 1 offers a unique approach to treating its target indications. However, its mechanism of action is not well understood. Further research is needed to fully understand the potential of Combination 1 in the pharmaceutical market.
At a glance
| Generic name | combination-1 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Combination therapy |
| Target | Multiple molecular targets |
| Phase | FDA-approved |
Approved indications
- Indication 1
- Indication 2
- Indication 3
Common side effects
Drug interactions
- Aspirin
- Warfarin
- Ibuprofen
- Clopidogrel
- Pentoxifylline
- Dipyridamole
- Ticlopidine
- Alteplase
- Urokinase
- Streptokinase
- Tenecteplase
- Reteplase
Key clinical trials
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers (PHASE1, PHASE2)
- A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer (PHASE1, PHASE2)
- Tasting Plant Forward Meals (NA)
- Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children ״DYMOND Study״ (PHASE2)
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood (PHASE1)
- Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |